Thiazolidinediones and Corticosteroids for Eosinophilic Esophagitis Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Eosinophilic esophagitis (EoE) is characterized by fibrosis and inflammation, leading to complications such as strictures and food impactions, for which current treatments often have variable effects and may not adequately address fibrosis.
Innovation Solution
The use of thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, in combination with corticosteroids, specifically budesonide, to treat eosinophilic inflammatory diseases and fibrosis, with the TZDs administered locally or systemically to inhibit fibrotic formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for eosinophilic esophagitis, then inflammation can be addressed, but fibrosis is not adequately treated and treatment effects are variable
Solution Approach 1:
The patent applies parameter changes by introducing a new therapeutic agent (thiazolidinediones) with different pharmacological properties compared to current treatments. TZDs act through PPAR-gamma activation to directly target fibrotic pathways, representing a change in the mechanistic parameter of treatment action from anti-inflammatory to anti-fibrotic
Solution Approach 2:
The patent employs composite materials by combining thiazolidinediones with corticosteroids in a single formulation. This composite approach allows simultaneous delivery of both anti-inflammatory (corticosteroid) and anti-fibrotic (TZD) agents, addressing multiple pathological aspects of EoE together
2Object-generated harmful factors
If thiazolidinediones are administered to inhibit fibrosis, then fibrotic complications are addressed, but the treatment approach becomes more complex
Solution Approach 1:
The patent merges two separate treatment approaches (TZD monotherapy and corticosteroid therapy) into a single combined formulation. This merging integrates the anti-fibrotic and anti-inflammatory mechanisms into one unified treatment regimen, simplifying administration despite the added therapeutic complexity
3Reliability
If combination therapy with TZDs and corticosteroids is used, then both inflammation and fibrosis are treated, but treatment cost and formulation complexity increase
Solution Approach 1:
The patent applies segmentation by formulating the combination therapy in a controlled-release or targeted-delivery system that segments the release or action of the two agents. This allows independent optimization of each component's delivery while maintaining their synergistic effects in a single formulation
Data Source
AI summary
The disclosure relates to methods and compositions to treat an eosinophilic disease or disorder. More particularly, the disclosure provides methods and compositions for treating eosinophilic esophagitis.